Sensorion

Sensorion Net Change in Cash

The Net Change in Cash of Sensorion (ALSEN.PA) as of Oct 25, 2026 is 5.86 M EUR. In the previous year, Net Change in Cash was 29.80 M EUR — a change of -80.32% (lower).

Net Change in Cash

5.86 MEUR

YoY

-80.32%

Last updated:

Net Change in Cash of Sensorion is 2025 5.86 M EUR. Net Change in Cash of Sensorion was 2024 29.80 M EUR. It decreases by -80.32% lower compared to the previous year.

The Sensorion Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2018
-4.88 M EUR
Jan 1, 2019
22.73 M EUR
Jan 1, 2020
31.75 M EUR
Jan 1, 2021
-12.17 M EUR
Jan 1, 2022
-23.80 M EUR
Jan 1, 2023
10.77 M EUR
Jan 1, 2024
29.80 M EUR
Jan 1, 2025
5.86 M EUR
The Sensorion Net Change in Cash history
YEARNet Change in CashYoY
5.86 MEUR-80.32%
29.80 MEUR+176.65%
10.77 MEUR-145.26%
-23.80 MEUR+95.48%
-12.17 MEUR-138.35%
31.75 MEUR+39.70%
22.73 MEUR-565.50%
-4.88 MEUR+423.44%
-932,646.00EUR-82.60%
-5.36 MEUR-140.69%
13.17 MEUR+4,675.36%
275,815.00EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Sensorion Stock analysis

What does Sensorion do? The company Sensorion SA is a French biotechnology company that specializes in developing innovative therapies for hearing and balance disorders. It was founded in 2009 and is headquartered in Montpellier. Sensorion SA's business model is based on researching and developing new drugs that can be used to treat inner ear diseases. These diseases often have severe effects on the quality of life and social interaction of those affected and represent a significant unmet medical need. Sensorion SA aims to develop innovative and effective therapies to address this need. The company specializes in two main areas: hearing disorders and balance disorders. In the field of hearing disorders, Sensorion SA focuses on developing drugs to treat sensorineural hearing loss. These disorders can be caused by various factors such as aging, noise exposure, or genetic predisposition and affect the inner ear. Sensorion SA has a promising pipeline of drugs in clinical development based on different mechanisms of action. These drugs aim to protect the inner ear and restore hearing function. In the field of balance disorders, Sensorion SA focuses on developing new drugs to treat dizziness and vestibular disorders. These disorders can be caused by factors such as aging, medications, or neurological diseases and affect the balance system in the inner ear. Sensorion SA also has a promising pipeline of drugs in clinical development in this area. Sensorion SA's products are not yet available on the market as they are still in development and undergoing clinical trials. However, the company works closely with academic and industry partners to test and validate its drugs. The development of new drugs is a lengthy and costly process that can take many years. However, Sensorion SA is confident that its therapies have the potential to improve the lives of many people. Overall, Sensorion SA has a promising business model based on the development of innovative therapies for hearing and balance disorders. The company has a promising pipeline of drugs in clinical development and works closely with partners to test and validate its products. If successful, their drugs could have a significant impact on the lives of people suffering from these diseases. Sensorion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sensorion stock

Net Change in Cash of Sensorion is 5.86 M EUR in 2025.

Net Change in Cash of Sensorion changed from 29.80 M EUR to 5.86 M EUR, representing a -80.32% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Sensorion since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Sensorion historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Sensorion

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Sensorion